MedTrace Logo

The Association Between Different Markers With Development of Maternal and Neonatal Complications in Women With Severe Preeclampsia

NCT07125599 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 284

Last updated 2025-08-27

No results posted yet for this study

Summary

pregnant women diagnosed with severe preeclampsia were subjected to • Full history taking including a detailed history of the hypertension state during the current pregnancy (onset, course, current medication, and whether the blood pressure is controlled or not).gravidity , parity mode of delivery any medical disorders, the presence of headache ,blurring of vision and epigastric pain.

* Complete physical examination: general (including BMI \& blood pressure measurement) and obstetric examinations.
* Routine obstetric ultrasound and Doppler indices Including umbilical artery Doppler (RI).
* Laboratory investigations :

1\. Complete blood count (CBC). 2 albuminuria will be detected by dipstick kits . 3. Liver enzymes \& kidney function. 4.PT,PC,INR.
* Pelvic-Abdominal ultrasound to assess the presence of ascites Ultrasound examination will be performed by a consultant obstetrician to detect free fluid in the peritoneal cavity, especially at hepato-renal pouch, sub-splenic area, or para-colic gutters.

The presence of ascites will be further confirmed at the time of delivery.

3-All labours will be attended by an expert neonatologist and the following will be recorded:

* APGAR score at (1 min).
* The further need for neonatal intensive care unit (NICU) admission.
* Perinatal death

Conditions

  • Severe Preeclampsia

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Ahmed Maged, MD · Cairo University

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-02
Primary Completion
2025-04-30
Completion
2025-05-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07125599 on ClinicalTrials.gov